Carnegie Investment Counsel Grows Stake in AbbVie Inc. $ABBV

Key Points

• Carnegie Investment Counsel boosted its stake in AbbVie by 17.5% to 163,620 shares, valued at about $37.39 million at the end of the quarter.
• AbbVie cut Q1 and FY2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), a primary near‑term negative that has produced mixed analyst reactions and a consensus target of $253 ("Moderate Buy").
• Significant insider selling occurred—EVP Perry C. Siatis sold 22,381 shares (~$5.15M) and SVP David Ryan Purdue sold 5,230 shares—leaving corporate insiders with just 0.06% ownership.

Carnegie Investment Counsel grew its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 17.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,620 shares of the company's stock after purchasing an additional 24,426 shares during the period. Carnegie Investment Counsel's holdings in AbbVie were worth $37,386,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ABBV. City Holding Co. lifted its stake in AbbVie by 4.4% in the fourth quarter. City Holding Co. now owns 45,141 shares of the company's stock worth $10,314,000 after purchasing an additional 1,887 shares during the last quarter. Apollon Financial LLC lifted its stake in AbbVie by 60.9% in the fourth quarter. Apollon Financial LLC now owns 2,385 shares of the company's stock worth $545,000 after purchasing an additional 903 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in AbbVie by 1.0% in the fourth quarter. Venturi Wealth Management LLC now owns 90,308 shares of the company's stock worth $20,634,000 after purchasing an additional 915 shares during the last quarter. Premier Path Wealth Partners LLC lifted its stake in AbbVie by 4.3% in the fourth quarter. Premier Path Wealth Partners LLC now owns 11,813 shares of the company's stock worth $2,699,000 after purchasing an additional 482 shares during the last quarter. Finally, Apollon Wealth Management LLC lifted its stake in AbbVie by 36.5% in the fourth quarter. Apollon Wealth Management LLC now owns 111,977 shares of the company's stock worth $25,586,000 after purchasing an additional 29,932 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ABBV has been the subject of several recent research reports. Sanford C. Bernstein reissued a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating for the company in a research note on Thursday, February 5th. Piper Sandler upped their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Finally, Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $253.00.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie's successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie's guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie's guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

AbbVie Price Performance

ABBV stock opened at $208.22 on Friday. AbbVie Inc. has a 1 year low of $168.54 and a 1 year high of $244.81. The company has a market cap of $368.16 billion, a P/E ratio of 88.23, a PEG ratio of 0.76 and a beta of 0.38. The firm has a 50-day moving average of $220.35 and a 200 day moving average of $224.01.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the firm earned $2.16 earnings per share. AbbVie's revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.